Navigation Links
ISTA Pharmaceuticals Announces Conference Call and Webcast of Third Quarter 2009 Financial Results
Date:10/2/2009

IRVINE, Calif., Oct. 2 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), today announced it will release third quarter 2009 financial results after market close on November 3, 2009. In conjunction, the Company will host a conference call at 5:00 p.m. Eastern Time to discuss these results and provide a pipeline update.

Date: Tuesday, November 3, 2009

Time: 5:00 p.m. Eastern Time

Conference call access:

Internet: www.istavision.com

Domestic dial-in: 800-510-9691

International dial-in: 617-614-3453

Passcode: 62898415

To access the 24-hour audio replay, U.S. and Canadian participants may dial 888-286-8010; international participants may dial 617-801-6888. The access code for the replay is 52451599. This conference call also will be webcast live and archived on ISTA's website until December 3, 2009.

About ISTA Pharmaceuticals

ISTA Pharmaceuticals is the fourth largest branded ophthalmic pharmaceutical business in the U.S. ISTA's four marketed products plus its product candidates include therapies for inflammation, ocular pain, glaucoma, allergy, and dry eye. The Company is developing a strong product pipeline to fuel future growth and market share, thereby continuing its growth to become the leading niche ophthalmic pharmaceutical company in the U.S. For additional information regarding ISTA, please visit ISTA Pharmaceuticals' website at http://www.istavision.com.

SOURCE ISTA Pharmaceuticals, Inc.


'/>"/>
SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Alexza Pharmaceuticals to Present at the Fourth Annual JMP Securities Healthcare Focus Conference
2. Biostar Pharmaceuticals, Inc. Receives Patent for Aoxing Ganbao
3. Intercept Pharmaceuticals FXR Agonist INT-747 Meets Primary Endpoint in a Phase II Clinical Trial in Type 2 Diabetic Patients with Nonalcoholic Fatty Liver Disease
4. Merriman Curhan Ford Acted as Financial Advisor to TorreyPines Therapeutics, Inc. in the Completed Merger With Raptor Pharmaceuticals Corp.
5. Sanofi-aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM-121, an Anti-ErbB3 Monoclonal Antibody
6. Fovea Pharmaceuticals to be Acquired by sanofi-aventis
7. Sagent Pharmaceuticals Launches Vinorelbine Injection, USP
8. Cadence Pharmaceuticals to Webcast October 7th Analyst Day
9. Raptor Pharmaceuticals Corp. and TorreyPines Complete Merger
10. Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December
11. Arena Pharmaceuticals to Host Conference Call and Webcast on Friday, September 18, 2009, to Discuss Results from the BLOSSOM Phase 3 Trial of Lorcaserin for Weight Management
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)...  Nearly 30 million people in the ... diabetes. 1 However, nearly 40% of diabetes patients ... and significant glucose variability. 2 These patients are at ... If left untreated, hyperglycemia can lead to cardiovascular disease, ... 3 As part of Diabetes Awareness ...
(Date:12/6/2016)... Dec. 6, 2016  Arcturus Therapeutics, Inc. ("Arcturus" ... announced today that it entered into collaboration with ... for the treatment of NASH and other gastrointestinal ... platform LUNAR™ and UNA Oligomer chemistry. The financial ... long-standing commitment to and expertise in GI disorders, ...
(Date:12/6/2016)... 2016 Breast Pump Market size is estimated ... by Global Market Insights, Inc. Continue Reading ... ... , , ... women employment rates and rising consumer awareness regarding importance of breast feeding will ...
Breaking Medicine Technology:
(Date:12/6/2016)... CA (PRWEB) , ... December 06, 2016 , ... Individuals ... protective measures, such as drinking more water or limiting their exposure to the sun, ... California health and beauty group Beverly Hills Physicians (BHP) notes that, while preventive measures ...
(Date:12/6/2016)... ... December 06, 2016 , ... Mount Sinai Health System today ... of Neurosurgery, where clinicians can confer and order 3D models for their cases. ... basis with quick turnaround times. This resource will be the first of its ...
(Date:12/6/2016)... , ... December 06, 2016 , ... Why does the ... Proietto, MB BS, PhD, FRACP, includes a fresh look into the cause of obesity ... evidence-based strategy providing readers with the knowledge needed to lead a healthy life. Proietto ...
(Date:12/6/2016)... ... December 06, 2016 , ... The NALA, a boutique marketing agency, is ... Foundation (TBCF), a nonprofit 501(C)(3) organization providing financial and emotional support to families ... To assist TBCF, the NALA recently hosted a Thanksgiving food drive that resulted in ...
(Date:12/6/2016)... ... December 06, 2016 , ... The V ... announce its Not a Moment to Lose fundraising campaign. As the V Foundation’s ... to declaring victory over cancer. The campaign aims to raise $200 million by ...
Breaking Medicine News(10 mins):